Treatment withedaravone, approved for amyotrophic lateral sclerosis (ALS) patients, at thetime of collagenase injection showed improved ICH pathology and functionaloutcomes in rats,25 and further studies identified that neuroprotection was similar to MCC950treatment, an NLRP3 specific inhibitor, improving neurological function andneurodegeneration in a rat autologous blood model.87 It is important to note that collagenase injection results in anexacerbated neuroinflammatory response when compared to autologous bloodinjection and so could confound anti-inflammatory results. The gene discussed is NLRP3; the disease is amyotrophic lateral sclerosis.